Truace
Subscribe

Automation and AI in clinical microbiology laboratories

Source article: Automation and artificial intelligence in the clinical microbiology laboratory

Background Clinical microbiology laboratories face persistent pressure to shorten turnaround times, reduce manual workloads, and standardize diagnostic workflows. Total laboratory automation (TLA) and artificial intelligence (AI) are complementary responses to these demands. In this review, we examine how the evidence base for automation and AI in clinical microbiology is distributed along a maturity gradient and what this distribution implies for the next phase of implementation. Content Available evidence indi…

By the Truvace desk2 min read1 sourcePeer-reviewedTRV-2026-2096· cite & verify
Automation and artificial intelligence in the clinical microbiology laboratory
"LUA, Faculty of Food Technology Food microbiology laboratory" by Turaids is licensed under CC BY-SA 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/4.0/.
Trace impact readingContested
P 70The P score combines the specificity and measured human impact of the grounded problem claim with the strength of this Trace’s cited sources.

Both sides are scored from claims and sources, not community votes.

G 70The G score combines the specificity and measured human impact of the grounded gain claim with the strength of this Trace’s cited sources.

In brief

A review of the evidence on total laboratory automation and artificial intelligence in clinical microbiology sorts it along a maturity gradient. Observational and multi-center studies indicate faster culture turnaround and less manual work, and automated reading, identification, and susceptibility testing agree well with manual methods on common specimen types.

The findings matter because laboratories are under pressure to speed up and standardize diagnostics, yet the evidence that this improves patient care is thin. AI tools for plate reading and resistance prediction are mostly unvalidated in prospective settings, and the review calls for multi-center prospective studies that use clinical outcomes as endpoints.

Main points

  1. The size of the turnaround and workload benefit depends on specimen type and workflow configuration.
  2. Automated systems showed error rates below commonly cited acceptability thresholds.
  3. Evidence on AI performance in plate reading and resistance prediction is abundant but mostly not prospectively validated.
  4. Randomized trials of rapid testing and automation rarely demonstrate overall clinical superiority.
  5. Interoperability, quality control, and regulatory frameworks are still under development.

The gain

Automated microbiology platforms shorten culture turnaround times and reduce manual workload, with automated reading, identification, and susceptibility systems agreeing closely with manual standards.

The problem

Most AI models for plate reading and resistance prediction remain assistive without prospective validation, and randomized trials rarely show clinical superiority or consistent patient-oriented benefit.

The rundown

The review frames total laboratory automation and AI as complementary answers to pressure for shorter turnaround times, lower manual workloads, and standardized diagnostic workflows in clinical microbiology.

Evidence for automation is strongest on operational measures. Observational and multi-center studies show shorter culture times and less manual work, though the benefit varies with specimen type and workflow configuration, and automated reading and susceptibility testing matched manual standards for common specimens.

For AI, the volume of performance evidence in plate reading and resistance prediction is large, but most models are still assistive without prospective validation. Guidelines offer directional support only, while interoperability, quality control, and regulation are still developing.

The authors say the priority is no longer single-center performance validation. They call for multi-center prospective verification, interpretability, standardization, and comparisons that use clinical outcomes as endpoints, and describe AI-assisted evidence tools as preliminary.

What this doesn’t fix

Most AI models lack prospective validation, patient-oriented benefits are limited and inconsistent, and the review describes AI-assisted evidence tools as preliminary.

Sources

  1. Peer-reviewedFrontiers in Cellular and Infection Microbiology2026-10-20

The debate